Ensoma
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.
1 past transactions
Twelve bio
Acquisition in 2023
Twelve Bio is a biotechnology company specializing in CRISPR-Cas12a diagnostic technology, which enables the detection and modification of specific DNA sequences. This innovative approach utilizes an RNA-protein molecule, where the RNA functions as a search engine to locate targeted DNA sequences, while the protein acts as a precise cutting tool. Twelve Bio has developed a diagnostic test capable of identifying early-stage lung cancer through a simple blood test. Additionally, the company offers a gene-editing toolbox designed to address a variety of genetic disorders, facilitating the creation of tailored and safe therapeutic molecules. This technology aims to streamline the treatment process for patients with previously incurable diseases, ultimately reducing both time and costs associated with obtaining effective medical care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.